In Q1 of fiscal 2024, the quarter ended Mar 31, 2024, Panacea Life Sciences Holdings, Inc. reported revenue of $1.1 million, up 55.9% from the same quarter a year earlier. It recorded a net loss of $1.4 million. The operating loss came to $1.1 million, an operating margin of -100.1%. Diluted earnings per share were -$0.09.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Mar 31, 2024
|
Q1 FY2024
Mar 31, 2024
|
Q4 FY2023
Dec 31, 2023
|
Q3 FY2023
Sep 30, 2023
|
Q2 FY2023
Jun 30, 2023
|
Q1 FY2023
Mar 31, 2023
|
Q4 FY2022
Dec 31, 2022
|
Q3 FY2022
Sep 30, 2022
|
Q2 FY2022
Jun 30, 2022
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3
+50.4%
|
1
+55.9%
|
1
+195.7%
|
0
-5.0%
|
0
-15.0%
|
1
+45.2%
|
0
-49.7%
|
0
-37.7%
|
0
+49.8%
|
| Cost of revenue |
1
-8.7%
|
0
-13.6%
|
0
+93.3%
|
0
-36.9%
|
0
-40.8%
|
0
+23.4%
|
0
-66.3%
|
0
+4.6%
|
0
+33.3%
|
| Gross profit |
2
+199.5%
|
1
+195.3%
|
1
+393.7%
|
0
+209.8%
|
0
+47.0%
|
0
+124.7%
|
0
+964.1%
|
0
-83.3%
|
0
+112.8%
|
| Selling, general and administrative |
1
+62.7%
|
0
-3.3%
|
1
+372.3%
|
0
+5.8%
|
0
-29.1%
|
0
-44.1%
|
0
-72.5%
|
0
-10.0%
|
0
-38.9%
|
| Operating income |
-5
-0.4%
|
-1
+18.0%
|
-2
-28.5%
|
-1
-1.8%
|
-1
+13.4%
|
-1
+21.7%
|
-1
+36.0%
|
-1
-10.4%
|
-1
+13.9%
|
| Other income (expense) |
-2
+17.5%
|
-0
+22.5%
|
-0
-33.9%
|
-1
+43.5%
|
-1
-9.5%
|
-1
+55.8%
|
-0
-672.2%
|
-1
+28.7%
|
-1
-149.2%
|
| Pretax income |
-8
+5.9%
|
-1
+19.3%
|
-2
-29.6%
|
-2
+20.1%
|
-2
+5.0%
|
-2
+35.6%
|
-2
+18.5%
|
-3
+12.8%
|
-2
-7308.8%
|
| Net income |
-8
+5.9%
|
-1
+19.3%
|
-2
-29.6%
|
-2
+20.1%
|
-2
+5.0%
|
-2
+35.6%
|
-2
+18.5%
|
-3
+12.8%
|
-2
-7308.8%
|
| Basic EPS |
-0.45
+20.4%
|
-0.09
+25.0%
|
-0.13
-15.6%
|
-0.13
+27.8%
|
-0.11
+15.4%
|
-0.12
+25.0%
|
-0.11
|
-0.18
+0.0%
|
-0.13
|
| Diluted EPS |
—
|
-0.09
|
-0.13
|
-0.13
|
-0.11
|
—
|
—
|
—
|
—
|
| Weighted average shares, basic |
17
+18.2%
|
16
+10.2%
|
17
+12.1%
|
17
+11.8%
|
18
+17.9%
|
15
-11.5%
|
15
|
15
-12.1%
|
15
-11.5%
|
| Weighted average shares, diluted |
—
|
16
|
17
|
17
|
18
|
—
|
—
|
—
|
—
|
| Other measures | |||||||||
| Depreciation and amortization |
2
-0.6%
|
0
-9.2%
|
0
+3.3%
|
0
+0.6%
|
0
+3.1%
|
0
+3.4%
|
0
+8.6%
|
0
+7.4%
|
0
-11.0%
|
| EBITDA |
-4
-0.8%
|
-1
+22.3%
|
-1
-40.0%
|
-1
-2.4%
|
-1
+21.5%
|
-1
+30.0%
|
-1
+46.0%
|
-1
-11.7%
|
-1
+15.2%
|
| Interest coverage |
-3.31x
|
-2.46x
|
-4.29x
|
-3.57x
|
-2.93x
|
-3.39x
|
-3.63x
|
-2.32x
|
-2.18x
|
| Margins | |||||||||
| Gross margin |
56.53%
|
63.06%
|
56.94%
|
42.15%
|
50.81%
|
33.30%
|
34.11%
|
12.92%
|
29.39%
|
| Operating margin |
-192.25%
|
-100.09%
|
-184.07%
|
-406.52%
|
-269.11%
|
-190.41%
|
-423.52%
|
-379.18%
|
-264.13%
|
| Pretax margin |
-277.51%
|
-136.88%
|
-229.95%
|
-618.39%
|
-467.08%
|
-264.41%
|
-524.85%
|
-735.55%
|
-417.87%
|
| Profit margin |
-277.51%
|
-136.88%
|
-229.95%
|
-618.39%
|
-467.08%
|
-264.41%
|
-524.85%
|
-735.55%
|
-417.87%
|
| EBITDA margin |
-131.68%
|
-63.78%
|
-137.88%
|
-284.61%
|
-163.20%
|
-128.03%
|
-291.31%
|
-264.04%
|
-176.82%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- PLSH (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Greenwood Village, CO
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1552189
- Former names
- Exactus, Inc. (until Oct 26, 2021); Spiral Energy Tech., Inc. (until Mar 4, 2016); Solid Solar Energy, Inc. (until Aug 7, 2013)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.